ES2157422T3 - Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos. - Google Patents

Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.

Info

Publication number
ES2157422T3
ES2157422T3 ES96904495T ES96904495T ES2157422T3 ES 2157422 T3 ES2157422 T3 ES 2157422T3 ES 96904495 T ES96904495 T ES 96904495T ES 96904495 T ES96904495 T ES 96904495T ES 2157422 T3 ES2157422 T3 ES 2157422T3
Authority
ES
Spain
Prior art keywords
acid
phenylalcanoic
triglicerids
phenylalkyen
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96904495T
Other languages
English (en)
Inventor
Saul W Brusilow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brusilow Enterprises LLC
Original Assignee
Brusilow Enterprises LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23519346&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2157422(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brusilow Enterprises LLC filed Critical Brusilow Enterprises LLC
Application granted granted Critical
Publication of ES2157422T3 publication Critical patent/ES2157422T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/618—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety having unsaturation outside the six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBEN DOS NUEVAS FORMAS DE PROFARMACO PARA EL ACETATO DE FENILO, DE CONGENERES UNIFORMES DEL ACIDO FENILALCANOICO Y ACIDOS FENILALQUENOICOS, QUE SON LOS ESTERES FENILALCANOICOS O FENILALQUENOICOS DE GLICEROL, O LOS ESTERES ETILICOS DEL ACIDO FENILALCANOICO O ACIDOS FENILALQUENOICOS. ESTAS FORMAS DE LOS FARMACOS SUMINISTRAN UNA FORMA DE DOSIFICACION ADECUADA DE LOS FARMACOS. LOS PROFARMACOS DE LA INVENCION RESULTAN UTILES PARA TRATAR PACIENTES CON ENFERMEDADES DE ACUMULACION DE NITROGENO, PACIENTES CON CIERTAS BE - HEMOGLOBINOPATIAS, ANEMIA Y CANCER.
ES96904495T 1995-02-07 1996-02-06 Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos. Expired - Lifetime ES2157422T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38493595A 1995-02-07 1995-02-07

Publications (1)

Publication Number Publication Date
ES2157422T3 true ES2157422T3 (es) 2001-08-16

Family

ID=23519346

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96904495T Expired - Lifetime ES2157422T3 (es) 1995-02-07 1996-02-06 Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.

Country Status (9)

Country Link
US (3) US5968979A (es)
EP (1) EP0858441B1 (es)
AT (1) ATE201013T1 (es)
AU (1) AU4858796A (es)
CA (1) CA2212047C (es)
DE (1) DE69612755T2 (es)
ES (1) ES2157422T3 (es)
FR (1) FR16C0003I2 (es)
WO (1) WO1996024571A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642543B1 (en) 2000-09-26 2003-11-04 The Board Of Trustees Of The Leland Stanford Junior University Thin and thick gate oxide transistors on a functional block of a CMOS circuit residing within the core of an IC chip
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20030195255A1 (en) * 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
CA2486303C (en) 2002-05-22 2013-04-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
US20090260743A1 (en) * 2003-11-21 2009-10-22 William David Mawby Tire manufacturing method for improving the uniformity of a tire
WO2006052916A2 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Inc. Histone deacetylase inhibitors
EP2330892B1 (en) * 2008-04-29 2016-06-29 Horizon Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
LT2330892T (lt) * 2008-08-29 2016-11-25 Horizon Therapeutics, Inc. Gydymo būdai panaudojant vaistus - amoniako gaudykles
PT2760479T (pt) 2011-09-30 2017-07-21 Horizon Therapeutics Llc Métodos de monitorização da terapêutica com fármacos eliminadores de azoto
DK2846791T3 (en) 2012-04-20 2017-03-27 Horizon Therapeutics Llc HPN-100 FOR USE IN TREATMENT OF NITROGEN RETENTION DISORDER
PT2922576T (pt) * 2012-11-21 2018-01-24 Horizon Therapeutics Llc Métodos de administração e avaliação de fármacos sequestradores de azoto para o tratamento de encefalopatia hepática
SI2986325T1 (sl) 2013-10-14 2020-02-28 Immedica Pharma Ab Postopki zdravljenja motenj ciklusa sečnine
IN2013MU03442A (es) 2013-10-30 2015-07-17 Lupin Ltd
ES2833294T3 (es) 2013-11-14 2021-06-14 Ultragenyx Pharmaceutical Inc Composiciones sólidas de triglicéridos y usos de las mismas
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
US20170119899A1 (en) 2015-10-29 2017-05-04 The Johns Hopkins University Compositions and methods for treatment of peroxisomal disorders and leukodystrophies
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
DE69612755D1 (de) 2001-06-13
EP0858441A1 (en) 1998-08-19
AU4858796A (en) 1996-08-27
WO1996024571A1 (en) 1996-08-15
US5968979A (en) 1999-10-19
CA2212047C (en) 2010-11-16
CA2212047A1 (en) 1996-08-15
DE69612755T2 (de) 2001-08-23
US6060510A (en) 2000-05-09
FR16C0003I2 (fr) 2016-06-24
US6083984A (en) 2000-07-04
FR16C0003I1 (es) 2016-03-25
ATE201013T1 (de) 2001-05-15
EP0858441A4 (es) 1998-08-19
EP0858441B1 (en) 2001-05-09

Similar Documents

Publication Publication Date Title
ES2157422T3 (es) Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
ES2176343T3 (es) Composiciones sanadoras de tratamiento de heridas causadas por el acne que contienen un piruvano, un antioxidante y una mezcla de acidos grasos.
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
PA8435301A1 (es) Derivados del acido arilsulfonilamino hidroxamico.
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
CY1110019T1 (el) Συνδυασμενη θεραπεια με υποκατεστημενες οξαζολιδινονες
ATE429922T1 (de) Topische gel-abgabesysteme zur behandlung von hauterkrankungen
BR0212617A (pt) Compostos de pirazolila substituìdo para o tratamento de inflamação
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CY1106107T1 (el) Φαρμακολογικες μορφοποιησεις που πepιλαμβανουν ρεσβepατρολη και χρηση αυτων
UY28213A1 (es) Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
ES2164097T3 (es) Uso de anestesicos topicos para la fabricacion de un medicamento para el tratamiento del asma bronquial.
ES2178724T3 (es) Acidos arilsulfonamido hidroxamicos alfa-sustituidos como inhibidores de factor de necrosis tumoral alfa y de metaloproteinasas de matriz.
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
BR0215404A (pt) processo e dispositivo para reduzir dosagem terapêutica
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
SE9701161D0 (sv) New use I
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
ES2177594T3 (es) Combinaciones de sustancias y asoactivas con acidos grasos para prevenir la caida del cabello.
MXPA02006610A (es) Sustancias para uso al tratar psoriasis.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
NO20043792L (no) New heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in medicine
ES2194157T3 (es) Composiciones para el cuidado de la piel que contienen un retinoide.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 858441

Country of ref document: ES